Bryant John M, Ruffolo Luis, Soares Kevin, Hoffe Sarah, Lowy Andrew M
Department of Radiation Oncology, Section of Gastrointestinal Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Department of Surgery, Hepatopancreatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
J Clin Invest. 2025 Jul 15;135(14). doi: 10.1172/JCI191944.
Despite advances in multidisciplinary oncology care, curing patients diagnosed with pancreatic duct adenocarcinoma (PDAC) remains all too uncommon. In this Review, we discuss evolving concepts to guide the care of patients with operable PDAC, focusing on adjuvant and neoadjuvant systemic therapies, the ever-controversial topic of radiation therapy, and the emerging role of cancer vaccines. Given the promise of biomarkers to better predict therapeutic response, the development of KRAS inhibitors, our ability to deliver higher doses of radiation therapy more precisely and safely, and the technology to rapidly produce highly personalized cancer vaccines, there is reason to expect that the guidelines for the care of our patients with operable PDAC will change rapidly in the next few years.
尽管多学科肿瘤护理取得了进展，但治愈被诊断为胰腺导管腺癌（PDAC）的患者仍然极为罕见。在本综述中，我们讨论不断发展的概念，以指导可手术切除的PDAC患者的护理，重点关注辅助和新辅助全身治疗、一直存在争议的放射治疗话题以及癌症疫苗的新兴作用。鉴于生物标志物有望更好地预测治疗反应、KRAS抑制剂的研发、我们更精确且安全地给予更高剂量放射治疗的能力以及快速生产高度个性化癌症疫苗的技术，有理由期待在未来几年里，我们针对可手术切除的PDAC患者的护理指南将迅速改变。
